J1940 is terminated (historical record)
Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J1940
20 MG
No published MUE for J1940. CMS keeps some MUE values confidential, so this does not mean there is no daily unit limit.
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Most recent Medicare Part B payment limit · Q1 2025
$0.386per 20 MG
Effective Jan 1, 2025 – Mar 31, 2025 · ASP methodology (per CMS file) · based on Q3 2024 ASP data · coinsurance 20.000%
Not in the latest payment limit file (Q4 2026). Shown for history only.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.386 | 20 MG | 20% | −2.5% | — |
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.396 | 20 MG | 20% | −9.6% |
Medicare hospital outpatient (OPPS)
No authoritative public data was located for this field.
Washington Apple Health · professional claims
Not on HCA's professional administered drug fee schedule.
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
No CMS NDC–HCPCS crosswalk rows were located. CMS notes its crosswalks are not a comprehensive list of all NDCs.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 16729-0500-08 | FurosemideACCORD HEALTHCARE INC | 2 × 25 | 1 | 25 | ASP | Q4 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 16729-0501-43 | FurosemideACCORD HEALTHCARE INC | 4 × 10 | 2 | 20 | ASP | Q4 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 16729-0502-43 | FurosemideACCORD HEALTHCARE INC | 10 × 10 | 5 | 50 | ASP | Q4 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 70121-1163-05 | FurosemideAMNEAL BIOSCIENCES | 2 × 25 | 1 | 25 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedFurosemide |
| 70121-1164-05 | FurosemideAMNEAL BIOSCIENCES | 4 × 25 | 2 | 50 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedFurosemide |
| 70121-1076-05 | FurosemideAMNEAL PHARMACEUTICALS, LLC | 10 × 25 | 5 | 125 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | Excluded listingFurosemide |
| 70860-0302-02 | FurosemideAthenex Pharmaceutical Division, LLC | 2 × 25 | 1 | 25 | ASP | Q2 2022 – Q1 2025Not in Q4 2026 file | Excluded listingFurosemide |
| 70860-0302-04 | FurosemideAthenex Pharmaceutical Division, LLC | 4 × 25 | 2 | 50 | ASP | Q2 2022 – Q1 2025Not in Q4 2026 file | Excluded listingFurosemide |
| 70860-0302-10 | FurosemideAthenex Pharmaceutical Division, LLC | 10 × 25 | 5 | 125 | ASP | Q2 2022 – Q1 2025Not in Q4 2026 file | Excluded listingFurosemide |
| 83634-0302-02 | FurosemideAVENACY | 2 × 25 | 1 | 25 | ASP | Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 83634-0302-04 | FurosemideAVENACY | 4 × 25 | 2 | 50 | ASP | Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 83634-0302-10 | FurosemideAVENACY INC. | 10 × 25 | 5 | 125 | ASP | Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 36000-0282-25 | FurosemideBaxter Healthcare Corporation | 2 × 25 | 1 | 25 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 36000-0283-25 | FurosemideBaxter Healthcare Corporation | 4 × 25 | 2 | 50 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 36000-0284-25 | FurosemideBaxter Healthcare Corporation | 10 × 25 | 5 | 125 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 72572-0190-25 | FurosemideCivica, Inc. | 4 × 25 | 2 | 50 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 55150-0322-25 | FurosemideEugia US LLC | 2 × 25 | 1 | 25 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 55150-0323-25 | FurosemideEugia US LLC | 4 × 25 | 2 | 50 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 55150-0324-25 | FurosemideEugia US LLC | 10 × 25 | 5 | 125 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 63323-0280-02 | FurosemideFreseniUS Kabi USA, LLC | 2 × 25 | 1 | 25 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 63323-0280-04 | FurosemideFreseniUS Kabi USA, LLC | 4 × 25 | 2 | 50 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 63323-0280-10 | FurosemideFreseniUS Kabi USA, LLC | 10 × 25 | 5 | 125 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 63323-0280-16 | FurosemideFreseniUS Kabi USA, LLC | 2 × 25 | 1 | 25 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 63323-0280-26 | FurosemideFreseniUS Kabi USA, LLC | 4 × 25 | 2 | 50 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 63323-0280-36 | FurosemideFreseniUS Kabi USA, LLC | 10 × 25 | 5 | 125 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 00404-9861-10 | FurosemideHenry Schein Inc. | 10 × 1 | 5 | 5 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | Excluded listingFurosemide |
| 00404-9862-10 | FurosemideHenry Schein Inc. | 10 × 1 | 5 | 5 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 00404-9863-04 | FurosemideHenry Schein Inc. | 4 × 1 | 2 | 2 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 00404-9864-02 | FurosemideHenry Schein Inc. | 2 × 1 | 1 | 1 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 52584-0283-25 | FurosemideHENRY SCHEIN, INC. | 4 × 1 | 2 | 2 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingFurosemide |
| 23155-0473-41 | FurosemideHeritage Pharmaceuticals Inc. | 2 × 25 | 1 | 25 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 23155-0473-42 | FurosemideHeritage Pharmaceuticals Inc. | 4 × 25 | 2 | 50 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 23155-0473-44 | FurosemideHeritage Pharmaceuticals Inc. | 10 × 25 | 5 | 125 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1226-03 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 10 × 25 | 5 | 125 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1227-01 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 2 × 1 | 1 | 1 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1572-01 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 2 × 1 | 1 | 1 | ASP | Q2 2024 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1572-03 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 2 × 25 | 2 | 50 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1574-01 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 4 × 1 | 2 | 2 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1574-03 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 4 × 25 | 2 | 50 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 51662-1575-01 | FurosemideHF Acquisition Co. LLC, DBA HealthFirst | 10 × 1 | 5 | 5 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 70756-0618-25 | FurosemideLIFESTAR PHARMA | 2 × 25 | 1 | 25 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 70756-0619-25 | FurosemideLIFESTAR PHARMA | 4 × 25 | 2 | 50 | ASP | Q1 2024 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 70756-0620-25 | FurosemideLIFESTAR PHARMA | 10 × 25 | 5 | 125 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 71288-0203-03 | FurosemideMeitheal Pharmaceuticals Inc. | 2 × 25 | 1 | 25 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 71288-0203-05 | FurosemideMeitheal Pharmaceuticals Inc. | 4 × 25 | 2 | 50 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 71288-0203-11 | FurosemideMeitheal Pharmaceuticals Inc. | 10 × 25 | 5 | 125 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 72603-0133-25 | FurosemideNorthstar RxLLC | 2 × 25 | 1 | 25 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 72603-0251-25 | FurosemideNorthstar RxLLC | 4 × 25 | 2 | 50 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 72603-0474-25 | FurosemideNorthstar RxLLC | 10 × 25 | 5 | 125 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 00409-1639-10 | FurosemidePFIZER INC. | 10 × 10 | 5 | 50 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingFurosemide |
| 00409-9631-04 | FurosemidePFIZER INC. | 4 × 10 | 2 | 20 | ASP | Q1 2021 – Q1 2024Not in Q4 2026 file | Excluded listingFurosemide |
| 25021-0311-02 | FurosemideSagent Pharmaceuticals | 2 × 25 | 1 | 25 | ASP | Q1 2022 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 25021-0311-04 | FurosemideSagent Pharmaceuticals | 4 × 25 | 2 | 50 | ASP | Q1 2022 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
| 25021-0311-10 | FurosemideSagent Pharmaceuticals | 10 × 25 | 5 | 125 | ASP | Q1 2022 – Q1 2025Not in Q4 2026 file | ListedFurosemide |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2025 | Termination date set | D — Discontinued | Termination date Mar 31, 2025 |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1982 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| — |
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.438 | 20 MG | 20% | −28.0% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.608 | 20 MG | 20% | +6.1% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.573 | 20 MG | 20% | −1.5% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.582 | 20 MG | 20% | +17.6% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.495 | 20 MG | 20% | −13.9% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.575 | 20 MG | 20% | −12.9% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.660 | 20 MG | — | +4.4% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.632 | 20 MG | — | +5.3% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.600 | 20 MG | — | −5.8% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.637 | 20 MG | — | +23.7% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.515 | 20 MG | — | +8.0% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.477 | 20 MG | — | −13.3% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $0.550 | 20 MG | — | −28.4% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $0.768 | 20 MG | — | +18.3% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $0.649 | 20 MG | — | — | — |
|---|